Skip to main content

Table 1 Baseline characteristics, medical history and drug therapy of the study participants

From: Association between the APOE gene polymorphism and lipid profile and the risk of atrial fibrillation

Variables

AF patients (n = 706)

Controls (n = 661)

P

Baseline characteristics, n (%)

   

Age ≥ 65y

575(81.44)

396(59.91)

< 0.001

Male

414(58.64)

393(59.46)

0.783

SBP ≥ 140mm Hg

329(46.60)

307(46.44)

0.954

DBP ≥ 90mm Hg

242(34.28)

173(26.17)

< 0.001

APOE-ε4 carrier

226(32.01)

180(27.23)

0.053

Alcohol intake

   

Never

677(95.89)

630(95.31)

0.175

Former

15(2.12)

9(1.36)

Current

14(1.98)

22(3.33)

Smoking status

   

Never

542(76.77)

498(75.34)

0.101

Former

89(12.61)

70(10.59)

Current

75(10.62)

93(14.07)

Medical history, n (%)

   

Hypertension

424(60.06)

379(57.34)

0.307

Diabetes

206(29.18)

188(28.44)

0.764

CAD

390(55.24)

223(33.74)

< 0.001

HF

294(41.64)

63(9.53)

< 0.001

Drug Therapy, n (%)

   

Statin

16(2.27)

12(1.82)

0.556

ACEIs

190(26.91)

111(16.79)

< 0.001

ARBs

148(20.96)

149(22.54)

0.479

BBs

302(42.78)

179(27.08)

< 0.001

MRAs

275(38.95)

53(8.02)

< 0.001

Digoxin

197(27.90)

24(3.63)

< 0.001

Diuretics

324(45.89)

91(13.77)

< 0.001

  1. Values for age expressed as mean ± SD
  2. SBP: systolic blood pressure
  3. DBP: diastolic blood pressure
  4. CAD: coronary artery disease
  5. HF: heart failure
  6. ACEIs: angiotensin-converting enzyme inhibitors
  7. ARBs: angiotensin receptor blockers
  8. BBs: β-receptor blockers
  9. MRAs: mineralocorticoid antagonists